GABAergic signaling

GABAergic signaling constitutes the principal inhibitory neurotransmitter system in the mature mammalian central nervous system, providing the essential counterbalance to glutamatergic excitation and thereby shaping neural network dynamics, rhythmic oscillations, and information processing. γ-Aminobutyric acid (GABA) is synthesized exclusively from glutamate by glutamic acid decarboxylase (GAD), which exists in two isoforms, GAD65 and GAD67, with GAD67 maintaining basal GABA levels and GAD65 providing the readily releasable pool for synaptic transmission (Erlander et al., 1991; Soghomonian & Martin, 1998). Despite representing only 20-30% of all central synapses, GABAergic interneurons exert disproportionate control over neuronal excitability due to their strategic perisomatic and dendritic targeting of principal cells (Somogyi et al., 1998). GABA is packaged into synaptic vesicles by the vesicular inhibitory amino acid transporter (VIAAT) and released by calcium-dependent exocytosis; signaling is terminated by high-affinity sodium-dependent GABA transporters (GAT-1 on neurons, GAT-3 on astrocytes), which remove GABA from the cleft and permit recycling via the glutamate-glutamine cycle (Borden, 1996; Bak et al., 2006).

GABA acts through three receptor classes: ionotropic GABAA and GABAC receptors, which mediate fast chloride-dependent inhibition, and metabotropic GABAB receptors, which mediate slower G protein-coupled responses (Bormann, 2000; Bettler et al., 2004). GABAA receptors are pentameric assemblies, typically composed of two α, two β, and one γ subunit, with 19 known subunits providing enormous functional diversity; the most abundant subtype is α1β2γ2, which mediates classical benzodiazepine-sensitive inhibition (Olsen & Sieghart, 2008). Upon GABA binding, the receptor opens a chloride-permeable pore; the direction of chloride flux depends on the chloride gradient, which is determined by the potassium-chloride cotransporter KCC2. In immature neurons, elevated intracellular chloride renders GABA depolarizing, a developmental switch essential for early network formation (Rivera et al., 1999; Ben-Ari, 2002). GABAB receptors are obligate heterodimers (GABAB1/GABAB2) that couple to Gαi/o, inhibiting adenylyl cyclase, modulating calcium channels, and activating GIRK potassium channels, producing slow hyperpolarization (Luscher et al., 1997). A distinguishing feature of GABAergic signaling is the extensive heterogeneity of interneurons, classified by morphology and markers such as parvalbumin (PV+), somatostatin (SST+), and vasoactive intestinal peptide (VIP+); PV+ basket cells provide powerful perisomatic inhibition controlling spike output, while SST+ and VIP+ interneurons modulate dendritic integration and disinhibition, respectively (Ascoli et al., 2008; Tremblay et al., 2016). Beyond fast synaptic ("phasic") inhibition, extrasynaptic GABAA receptors containing δ or α4/6 subunits mediate persistent "tonic" inhibition in response to ambient GABA, setting global neuronal excitability (Farrant & Nusser, 2005; Belelli et al., 2009).

GABAergic signaling is the primary target for several major drug classes. Benzodiazepines bind at the α-γ subunit interface, allosterically enhancing channel opening frequency to produce anxiolytic, sedative, and anticonvulsant effects (Rudolph & Knoflach, 2011). Barbiturates enhance channel opening duration, while general anesthetics like propofol also potentiate GABAA function; flumazenil acts as a benzodiazepine site antagonist (Möhler et al., 2002). The GABAB agonist baclofen is used for spasticity (Bowery, 2006). Dysfunctional GABAergic inhibition underlies numerous neurological and psychiatric disorders. Reduced inhibition predisposes to epilepsy, and mutations in GABAA receptor genes (e.g., GABRG2) are associated with genetic epilepsy syndromes (Macdonald et al., 2010). Impaired GABAergic function, particularly in PV+ and SST+ interneurons, is implicated in schizophrenia, while excitation-inhibition imbalance contributes to autism spectrum disorders (Lewis et al., 2012; Rubenstein & Merzenich, 2003). In Alzheimer's disease, GABAergic circuit disruption contributes to network hyperexcitability (Villette & Villette, 2015). Therapeutic strategies include subunit-selective positive allosteric modulators with improved side-effect profiles and neuroactive steroids targeting extrasynaptic receptors, as exemplified by brexanolone for postpartum depression (Kanes et al., 2017). In conclusion, GABAergic signaling operates through diverse receptor subtypes, interneuron classes, and phasic versus tonic modes to provide essential inhibition, and its dysfunction is central to a wide spectrum of neuropsychiatric diseases, making it a critical target for therapeutic intervention.

References

Ascoli, G. A., Alonso-Nanclares, L., Anderson, S. A., et al. (2008). Petilla terminology: Nomenclature of features of GABAergic interneurons of the cerebral cortex. Nature Reviews Neuroscience, 9(7), 557–568.

Bak, L. K., Schousboe, A., & Waagepetersen, H. S. (2006). The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. Journal of Neurochemistry, 98(3), 641–653.

Belelli, D., Lambert, J. J., & Herd, M. B. (2009). The role of extrasynaptic GABA receptors in the regulation of neuronal excitability. Current Opinion in Pharmacology, 9(1), 47–53.

Ben-Ari, Y. (2002). Excitatory actions of GABA during development: The nature of the nurture. Nature Reviews Neuroscience, 3(9), 728–739.

Bettler, B., Kaupmann, K., Mosbacher, J., & Gassmann, M. (2004). Molecular structure and physiological functions of GABAB receptors. Physiological Reviews, 84(3), 835–867.

Borden, L. A. (1996). GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochemistry International, 29(4), 335–356.

Bormann, J. (2000). The 'ABC' of GABA receptors. Trends in Pharmacological Sciences, 21(1), 16–19.

Bowery, N. G. (2006). GABAB receptor: A site of therapeutic benefit. Current Opinion in Pharmacology, 6(1), 37–43.

Erlander, M. G., Tillakaratne, N. J. K., Feldblum, S., et al. (1991). Two genes encode distinct glutamate decarboxylases. Neuron, 7(1), 91–100.

Farrant, M., & Nusser, Z. (2005). Variations on an inhibitory theme: Phasic and tonic activation of GABAA receptors. Nature Reviews Neuroscience, 6(3), 215–229.

Kanes, S., Colquhoun, H., Gunduz-Bruce, H., et al. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial. The Lancet, 390(10093), 480–489.

Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences, 35(1), 57–67.

Luscher, C., Jan, L. Y., Stoffel, M., et al. (1997). G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron, 19(3), 687–695.

Macdonald, R. L., Kang, J. Q., & Gallagher, M. J. (2010). Mutations in GABAA receptor subunits associated with genetic epilepsies. Journal of Physiology, 588(11), 1861–1869.

Möhler, H., Fritschy, J. M., & Rudolph, U. (2002). A new benzodiazepine pharmacology. Journal of Pharmacology and Experimental Therapeutics, 300(1), 2–8.

Olsen, R. W., & Sieghart, W. (2008). International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit composition, pharmacology, and function. Pharmacological Reviews, 60(3), 243–260.

Rivera, C., Voipio, J., Payne, J. A., et al. (1999). The K+/Cl− co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature, 397(6716), 251–255.

Rubenstein, J. L. R., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes, Brain and Behavior, 2(5), 255–267.

Rudolph, U., & Knoflach, F. (2011). Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes. Nature Reviews Drug Discovery, 10(9), 685–697.

Soghomonian, J. J., & Martin, D. L. (1998). Two isoforms of glutamate decarboxylase: Why? Trends in Pharmacological Sciences, 19(12), 500–505.

Somogyi, P., Tamás, G., Lujan, R., & Buhl, E. H. (1998). Salient features of synaptic organisation in the cerebral cortex. Brain Research Reviews, 26(2-3), 113–135.

Tremblay, R., Lee, S., & Rudy, B. (2016). GABAergic interneurons in the neocortex: From cellular properties to circuits. Neuron, 91(2), 260–292.

Villette, V., & Villette, M. (2015). GABAergic dysfunction in Alzheimer's disease. Neurology International, 7(1), 17.